SGStephen K. Godin

Stephen K. Godin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Stephen K. Godin has a total of 54 co-authors. Here are the top co-authors by number of shared publications:

  • Kathryn L. Terry

    Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States; Boston Center for Endometriosis, Boston Children's Hospital and Brigham and Women's Hospital, Boston, MA, United States; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States

    2 shared publications
  • Kristeena R. Wright

    Vascular Biology Program, Department of Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA, United States

    2 shared publications
  • Michael Scott Rogers

    Vascular Biology Program, Boston Children's Hospital, Department of Surgery, Harvard Medical School; Boston, MA 02115, United States of America

    2 shared publications
  • Olivia K. Heintz

    Vascular Biology Program, Boston Children’s Hospital, Department of Surgery, Harvard Medical School, Boston, MA 02115, USA

    2 shared publications
  • Tiago Henrique Zaninelli

    Department of Immunology, Parasitology and General, State University of Londrina, Brazil

    2 shared publications
  • Adrian Beckmann

    The University of Texas MD Anderson Cancer Center 3 The Neurodegeneration Consortium, Therapeutics Discovery Division Houston, TX, USA

    1 shared publication

Latest Publications

  • Open Access

    Targeting NGF but not VEGFR1 or BDNF signaling reduces endometriosis-associated pain in mice

    by Tiago H. Zaninelli, Victor Fattori, Olivia K. Heintz, Kristeena R. Wright, Philip R. Bennallack, Danielle Sim, Hussain Bukhari, Kathryn L. Terry, Allison F. Vitonis, Stacey A. Missmer, et al.


  • Open Access

    Targeting NGF but not VEGF or BDNF signaling reduces endometriosis-associated pain in mice

    by Tiago H. Zaninelli, Victor Fattori, Olivia K. Heintz, Kristeena R. Wright, Philip R. Bennallack, Danielle Sim, Hussain Bukhari, Kathryn L. Terry, Allison F. Vitonis, Stacey A. Missmer, et al.

    Introduction: Endometriosis is a chronic inflammatory disease that affects ∼10% of women. A significant fraction of patients experience limited or no efficacy with current therapies. Tissue adjacent to endometriosis lesions often exhibits increased neurite and vascular density, suggesting that disease pathology involves neurotrophic activity and angiogenesis. Objectives: We aim to evaluate the potential for key tyrosine-kinase-receptor-coupled neurotrophic molecules to contribute to endometriosis-associated pain in mice. Methods: The levels of VEGFR1 regulators (VEGFA, VEGFB, PLGF, and sVEGFR1) were quantified by ELISA in peritoneal fluid from endometriosis patients undergoing surgery and used to calculate VEGFR1 occupancy. We used genetic depletion, neutralizing antibody, and pharmacological approaches to specifically block ligand (NGF or BDNF) or neurotrophic receptor (VEGFR1, TRKs) in a murine model of endometriosis-associated pain. Endometriosis-associated pain was determined using the von Frey filaments method, quantification of spontaneous abdominal pain-related behavior, and thermal discomfort. Diseases parameters were evaluated by lesion size and prevalence. Results: We found that entrectinib (pan-Trk inhibitor) or anti-NGF treatments reduced evoked pain, spontaneous pain, and thermal discomfort. In contrast, even though receptor occupancy revealing that VEGFR1 agonist levels are sufficient to support pain, blocking VEGFR1 signaling via antibody or tamoxifen-induced knockout did not reduce pain or lesion size in mice. Targeting BDNF-TrkB with an anti-BDNF antibody also proved ineffective. Conclusions: This suggests NGF-TrkA signaling, but not BDNF-TrkB or VEGF-VEGFR1, mediates endometriosis-associated pain. Moreover, entrectinib blocks endometriosis-associated pain and reduces lesion sizes. Our results also indicated that entrectinib-like molecules are promising candidates for endometriosis treatment. Credit author statement: Conceptualization: T.H. Zaninelli, V. Fattori, and M.S. Rogers; investigation and data curation: T.H. Zaninelli, V. Fattori, O.K. Heintz, K.R. Wright; A.C. Andrello, W.A. Verri Jr, M.S. Rogers; funding acquisition: M.S. Rogers,, S.A. Missmer, R.M. Anchan; methodology: T.H. Zaninelli, V. Fattori, and M.S. Rogers; human sample collection: S.A. Missmer, A.F. Vitonis, K.L. Terry, R.M. Anchan; animal breading and VEGFR1 ablation: D. Sim and H. Bukhari; resources: A.C. Andrello; D. Bree, T. Zheng, J. Wagner, W.A. Verri Jr, and M.S. Rogers; project administration: T.H. Zaninelli; supervision: V. Fattori, W.A. Verri Jr, and M.S. Rogers; visualization: T.H. Zaninelli, V. Fattori, W.A. Verri Jr, and M.S. Rogers; writing–original draft: T.H. Zaninelli; writing – editing and reviewing: all authors. All authors have read and approved the final version of the manuscript.


  • Open Access

    A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation

    by William T. Ralvenius, Alison E. Mungenast, Hannah Woolf, Margaret M. Huston, Tyler Z. Gillingham, Stephen K. Godin, Jay Penney, Hugh P. Cam, Fan Gao, Celia G. Fernandez, et al.

    Pervasive neuroinflammation occurs in many neurodegenerative diseases, including Alzheimer’s disease (AD). SPI1/PU.1 is a transcription factor located at a genome-wide significant AD-risk locus and its reduced expression is associated with delayed onset of AD. We analyzed single-cell transcriptomic datasets from microglia of human AD patients and found an enrichment of PU.1-binding motifs in the differentially expressed genes. In hippocampal tissues from transgenic mice with neurodegeneration, we found vastly increased genomic PU.1 binding. We then screened for PU.1 inhibitors using a PU.1 reporter cell line and discovered A11, a molecule with anti-inflammatory efficacy and nanomolar potency. A11 regulated genes putatively by recruiting a repressive complex containing MECP2, HDAC1, SIN3A, and DNMT3A to PU.1 motifs, thus representing a novel mechanism and class of molecules. In mouse models of AD, A11 ameliorated neuroinflammation, loss of neuronal integrity, AD pathology, and improved cognitive performance. This study uncovers a novel class of anti-inflammatory molecules with therapeutic potential for neurodegenerative disorders.


  • Open Access

    The Shu complex promotes error-free tolerance of alkylation-induced base excision repair products

    by Stephen K. Godin, Zhuying Zhang, Benjamin W. Herken, James W. Westmoreland, Alison G. Lee, Michael J. Mihalevic, Zhongxun Yu, Robert W. Sobol, Michael A. Resnick, Kara A. Bernstein

    Here, we investigate the role of the budding yeast Shu complex in promoting homologous recombination (HR) upon replication fork damage. We recently found that the Shu complex stimulates Rad51 filament formation during HR through its physical interactions with Rad55-Rad57. Unlike other HR factors, Shu complex mutants are primarily sensitive to replicative stress caused by MMS and not to more direct DNA breaks. Here, we uncover a novel role for the Shu complex in the repair of specific MMS-induced DNA lesions and elucidate the interplay between HR and translesion DNA synthesis. We find that the Shu complex promotes high-fidelity bypass of MMS-induced alkylation damage, such as N3-methyladenine, as well as bypassing the abasic sites generated after Mag1 removes N3-methyladenine lesions. Furthermore, we find that the Shu complex responds to ssDNA breaks generated in cells lacking the abasic site endonucleases. At each lesion, the Shu complex promotes Rad51-dependent HR as the primary repair/tolerance mechanism over error-prone translesion DNA polymerases. Together, our work demonstrates that the Shu complex's promotion of Rad51 pre-synaptic filaments is critical for high-fidelity bypass of multiple replication-blocking lesion.